A novel truncated form of apolipoprotein A-I transported by dense LDL is increased in diabetic patients by Cubedo Ràfols, Judit et al.
1762 Journal of Lipid Research Volume 56, 2015
Copyright © 2015 by the American Society for Biochemistry and Molecular Biology, Inc.
This article is available online at http://www.jlr.org
 Atherosclerotic CVD is the main cause of death in dia-
betic (DM) patients ( 1 ). Indeed, patients with diabetes 
show two to three times higher coronary risk than nondia-
betic (nonDM) patients ( 2 ). Several large clinical trials 
have demonstrated the importance of plasma lipoproteins 
in the pathogenesis of coronary artery disease (CAD) ( 3 ). 
It is well-known that high levels of LDLs are considered to 
be a key contributor to the initiation and progression of 
atherosclerosis ( 4 ), and are, therefore, one of the stron-
gest predictors of CAD in both DM and nonDM patients 
( 5 ). In contrast, elevated levels of HDLs strongly correlate 
with reduced cardiovascular risk ( 6 ). The structure and 
cholesterol transport ability of HDL particles are deter-
mined by the properties of their exchangeable apolipo-
protein components ( 7 ). ApoA-I is the main protein in 
HDLs, representing 70% of its total protein content, and 
is central to HDL assembly, remodeling, and metabolism 
( 8 ). In addition to its structural role, ApoA-I has a func-
tional role in reverse cholesterol transport by promoting 
the effl ux of cholesterol from peripheral cells into HDLs 
and activating LCAT ( 9 ). During reverse cholesterol trans-
port, ApoA-I transitions from lipid-free protein to spheri-
cal HDL particles through a particle remodeling process 
( 10 ). First, lipid-free/lipid-poor ApoA-I acquires phospho-
lipid and cholesterol through ABCA1 ( 11 ) and generates 
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following the same protocol, but in a 1.006–1.019 density gradi-
ent. LDL subclasses were isolated following the same methodol-
ogy as for total LDLs (density gradient of 1.019–1.063), but with 
density gradients of 1.019, 1.030, 1.041, and 1.052 for subfrac-
tions 1, 2, 3, and 4, respectively. 
 Lipoprotein purity was routinely analyzed by electrophoresis 
(2   l sample) in agarose gels using a commercial assay (SAS-MX 
Lipo 10 kit; Helena Biosciences), as described by the providers. In 
addition, LDL purity was checked by analyzing the LDL profi le in 
samples of randomly selected subjects (one subject per ultracentri-
fugation batch) by chromatography analysis by microgel fi ltration 
using a Superose 6 PC 3.2/30 column and an Agilent 1200 HPLC 
system, as previously described ( 24 ). Briefl y, 10   l of undiluted LDL 
sample fraction were loaded in the system and run with a constant 
fl ow of 100   l/min. Retention time for the LDL fraction (130 min) 
was compared with that for HDL (134 min) and VLDL (128 min). 
 The method of Karlsson et al. ( 25 ) was used for VLDL and 
LDL protein mapping, with minor modifi cations. Briefl y, 1 ml of 
either VLDLs or LDLs (1 g/l ApoB) was delipidated by mixing 
with 14 ml of ice-cold tributyl phosphate:acetone:methanol 
(1:12:1) and incubating for 90 min at   20°C, followed by cen-
trifugation at 2,800  g for 15 min . Protein pellets were washed se-
quentially with 1 ml of tributyl phosphate, acetone, and methanol, 
and then air dried. Precipitates were boiled in solution contain-
ing 0.325 M DTT, 4% chaps, and 0.045 M Tris for 3 min, cooled 
at room temperature, diluted (1:15) in urea/thiourea/chaps so-
lution, and incubated at 35°C for 15 min. The serum resulting 
after lipoprotein isolation was also collected for proteomic stud-
ies as the lipoprotein-depleted serum (LPDS) fraction. 
 Protein concentration was measured with a 2D-Quant kit (GE 
Healthcare). All processed samples were stored at   80°C until used. 
 Proteomic analysis 
 Proteomic analysis was performed in representative subgroups 
of the study population in complete serum [serum; 12 DM pa-
tients (6 type 1 and 6 type 2) and 6 nonDM subjects], LPDS (N = 
3 per group), and lipoprotein fractions (HDL and LDL, N   5 
per group in both cases; and VLDL, N = 3 per group). The pro-
teomic analysis of LDL subfractions was performed in 30 DM pa-
tients and 30 nonDM individuals pooled in three groups of 10 
subjects each in order to obtain enough protein. 
 Two-dimensional gel electrophoresis.  For analytical and prepara-
tive gels, respectively, a protein load of 120   g and 300   g of the 
urea/chaps (for human and rat serum, and human LPDS ex-
tracts) and urea/thiourea/chaps (for human HDL, LDL, and 
VLDL extracts and rat liver tissue extracts) were applied to 18 cm 
dry strips (pH 4–7 linear range; GE Healthcare). The second 
dimension was resolved in 10% SDS-PAGE gels. In a subset of 
samples, isoelectrofocusing (IEF) was performed in a pH zoom 
between 4.5 and 6.9 and 15% SDS-PAGE gels to specifi cally focus 
on the ApoA-I region. Gels were developed by fl uorescent stain-
ing (Flamingo; Bio-Rad). In two-dimensional gel electrophoresis 
(2-DE) analyses, the proteomic profi le of both groups was com-
pared by using the PD-Quest 8.0 software (Bio-Rad) that specifi -
cally analyzes the differences in protein patterns by using a single 
master that includes all the gels of each independent experiment 
(samples from control and DM patients). In this analysis, each 
spot in the gel is assigned a relative value that corresponds to the 
single spot volume compared with the volume of all spots in this 
gel. Afterwards, this value is subjected to background extraction 
and the fi nal intensity value is then normalized by the local re-
gression model (LOESS) method of the software. 
 MS analysis.  Proteins were identifi ed after in-gel tryptic diges-
tion and extraction of peptides from the gel pieces, as previously 
nascent HDLs. Second, cholesterol on nascent HDL is es-
terifi ed by LCAT to yield cholesteryl ester (CE) ( 12 ) and 
mature spherical HDLs. In pioneering studies, we reported 
that homologous VHDLs (HDL3, VHDL rich in ApoA-I) 
injections in rabbits, without modifying HDL-cholesterol 
plasma levels, delayed atherosclerotic plaque formation 
and induced atherosclerotic plaque regression ( 13 ). Years 
later, this effect was shown in humans treated with ApoA-I 
Milano ( 14 ). ApoA-I is also responsible for the recognition 
of HDLs by liver SRB1 receptors ( 15 ). Among all apolipo-
proteins, levels of ApoA-I correlate with the protective ef-
fect of HDLs against atherosclerosis ( 16 ). 
 ApoA-I is initially synthesized as a prepro-apolipopro-
tein of 267 amino acids (aas), and it is secreted in an im-
mature form after the removal of the signal peptide (fi rst 
18 aas) that is named pro-ApoA-I (aas 19-267). Finally, 
during its maturation process the pro-peptide is removed, 
resulting in the mature form of ApoA-I of 243 aas and a 
molecular mass of 28 kDa (aas 25-267) ( 17 ). Besides some 
posttranslational modifi cations during processing, abnor-
mal circulating ApoA-I variants have also been identifi ed. 
Recently, a C-terminal truncated form that expressed with 
reduced cholesterol esterifi cation rate and decreased LCAT 
activity has been described in a Japanese woman ( 18 ). It 
has also been described that chymase has the ability to 
cleave the C terminus of ApoA-I at Phe225, reducing its 
ability to promote cellular cholesterol effl ux ( 19 ). 
 Several studies have reported the impact of changes in 
HDLs on CVD. Specifi cally, HDLs from acute coronary 
syndrome patients have been shown to suffer a shift to an 
infl ammatory profi le and a functional impairment linked 
to a remodeled protein cargo in the different HDL sub-
fractions ( 20 ). Decreased antioxidant properties have been 
reported in HDLs of type 2 DM patients, a defect ascribed 
to tentative changes in HDL composition ( 21 ). 
 In this study, we hypothesized that the impaired HDL 
function described in DM patients might be due to struc-
tural changes in ApoA-I. 
 MATERIALS AND METHODS 
 DM patients and nonDM controls 
 The study population was comprised of a group of 55 DM pa-
tients with HbA1c >6% and a group of 58 nonDM individuals who 
attended to a routine health check. Diabetes mellitus was defi ned 
according to the American Diabetes Association (ADA) 1997 cri-
teria. Standard biochemical analyses were performed in the ana-
lytical chemistry hospital laboratory. The ethics committee of the 
Santa Creu i Sant Pau Hospital approved the project and the stud-
ies were conducted according to the principles of the Declaration 
of Helsinki. All participants gave written informed consent to 
take part in the study. 
 Blood collection and sample preparation 
 Venous blood samples were collected to prepare serum that 
was aliquoted and stored at   80°C. For proteomic studies, serum 
samples were prepared as previously described ( 22, 23 ). Total HDL, 
HDL2, and HDL3 subfractions were prepared, as previously de-
scribed, in KBr density gradients of 1.063–1.210, 1.063–1.125, 
and 1.125–1.210, respectively ( 22, 23 ). VLDLs were isolated 
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an Eclipse XDB-C18 C18 column and by MS/MS or high-resolution 
MS. The LIPIDVEIW database was used for identifi cation, and nor-
malization was performed as previously described ( 29 ). 
 Quantifi cation of ApoA-I serum levels 
 ApoA-I serum concentration in DM (N = 55) and nonDM 
(N = 59) patients was determined by competitive sandwich enzyme-
linked immunosorbent assay (AssayPro) using immobilized poly-
clonal antibodies, as described by the providers. The detection 
limit of the assay was 1.2   g/ml and the intra-assay and inter-assay 
coeffi cients of variation were 4.6 and 7.3%, respectively. 
 Cathepsin D ApoA-I digestion 
 ApoA-I cathepsin D digestion was performed by incubating 
10   g of purifi ed ApoA-I (ab50239; Abcam) with one unit of ca-
thepsin D (ab77871; Abcam) in a 0.1 M sodium formate buffer 
for 18 h at 37°C and a pH of 3.6. Hemoglobin digestion was used 
as a positive control of enzyme activity. After digestion, samples 
were resolved in 15% SDS-PAGE gels that were developed by 
fl uorescent staining (Flamingo; Bio-Rad). 
 ApoA-I binding assay 
 Human recombinant ApoA-I (ab168890; Abcam) was labeled 
with a fl uorescent dye (DyLight 488 microscale labeling kit; 
Thermo Scientifi c). After labeling, 100   g of ApoA-I were di-
gested with cathepsin D for 18 h at 37°C and a pH of 3.6. The 
same amount of labeled ApoA-I (100   g) was incubated in the 
same conditions but without cathepsin D. Then, full-length and 
truncated labeled ApoA-I were incubated with LDL and HDL 
fractions for 1 h at room temperature (50   g ApoA-I/100   g 
LDL or HDL). Afterwards, unbound ApoA-I was removed by fi l-
tration with a cut-off of 100 kDa (Amicon Ultra-0.5 Centrifugal 
fi lter devices; Merck-Millipore). The fl uorescent signal of the li-
poprotein-ApoA-I-labeled fraction was detected with Typhoon 
FLA 9500 (GE Healthcare) and the amount of ApoA-I was quan-
tifi ed using ImageQuant TL v7.01 (GE Healthcare). 
 TRAP-antioxidant capacity 
 Human recombinant ApoA-I (ab168890; Abcam) was incu-
bated for 18 h at 37°C and a pH of 3.6 with or without cathepsin 
D. LDLs (100   g) were oxidized with 20   M Cu 2 SO 4 for 4 h at 
37°C, alone or in the presence of full-length ApoA-I or cathepsin 
D-cleaved ApoA-I. Afterwards, LDL oxidation was stopped by in-
cubation with EDTA (1 mM) and butylated hydroxytoluene 
(BHT; 1 mM) for 1 h at 37°C. The antioxidant capacity of each 
sample (LDL alone or in the presence of full-length ApoA-I or 
cathepsin D-cleaved ApoA-I) was assessed by the total peroxyl 
radical-trapping antioxidant potential (TRAP) method. Briefl y, 
DCFH-DA (D-399; Invitrogen) was prepared by basic hydrolysis 
and added to the sample at 10   M. After an incubation period (2 h 
at 37°C), TRAP was determined with Typhoon FLA 9500 (GE 
Healthcare) and quantifi ed using ImageQuant TL v7.01 (GE 
Healthcare). The antioxidant capacity of cathepsin D was also 
assessed in order to avoid potential confounding effects. 
 Rat model and hepatic tissue extraction for cathepsin D 
activity measurement 
 Zucker diabetic fatty rats (N = 7) and their corresponding lean 
normoglycemic controls (N = 8) were fed with LabDiet® 5008 
chow and water given ad-libitum with 12 h day/night cycles. Animals 
were anesthetized with a combination of ketamine and medetomi-
dine (75 mg/kg and 0.5 mg/kg, ip) and then euthanized with an 
intracardiac overdose of sodium pentobarbital. Liver samples 
were extracted immediately after the animals were euthanized, 
and immediately frozen in liquid nitrogen and stored at   80°C. 
described ( 22, 23 ), by MALDI-TOF using an AutoFlex III Smart-
beam MALDI-TOF/TOF (Bruker Daltonics). Samples were applied 
to Prespotted AnchorChip plates (Bruker Daltonics) surround-
ing the calibrants provided on the plates. Spectra were acquired 
with fl exControl on refl ector mode (mass range,  m/z 850–4,000; 
refl ector 1, 21.06 kV; refl ector 2, 9.77 kV; ion source 1 voltage, 
19 kV; ion source 2 voltage, 16.5 kV; detection gain, 2.37×) with 
an average of 3,500 added shots at a frequency of 200 Hz. Each 
sample was processed with fl exAnalysis (v3.0; Bruker Daltonics) 
considering a signal-to-noise ratio over 3, applying statistical cali-
bration, and eliminating background peaks. For identifi cation, 
peaks between 850 and 1,000 were not considered because, in 
general, only matrix peaks are visible in this mass range . After 
processing, spectra were sent to the interface, BioTools (v3.2; 
Bruker Daltonics), and MASCOT search on Swiss-Prot 57.15 da-
tabase was done [taxonomy:  Homo sapiens , mass tolerance 50–
100, up to 2 miss cleavage; global modifi cation: carbamidomethyl 
(C); variable modifi cation: oxidation (M)]. Identifi cation was ac-
cepted with a score higher than 56. Analysis of the truncated form 
was investigated using the Sequence Editor tool of BioTools. For 
theoretical digestion of ApoA-I, the sequence reported as P02647 
in Swiss-Prot was used and the parameters for peptide generation 
were the same as for the MASCOT search. The peptides generated 
in Sequence Editor were then sent back to BioTools for compari-
son with the experimental data and MASCOT result. 
 Western blot analysis 
 Protein extracts were resolved by, one-dimensional gel elec-
trophoresis (1-DE) (LDL and VLDL samples) and 2-DE (LDL, 
VLDL, rat serum, and liver samples) under reducing conditions 
and electrotransferred to polyvinylidene difl uoride membranes 
in semi-dry conditions (semi-dry transfer system; Bio-Rad). Pro-
tein detection was performed using rabbit polyclonal antibody 
against total ApoA-I (178422, 1:1,000 dilution; Calbiochem) com-
bined with the Dye Double Western blot kit (Invitrogen). Band 
fl uorescence was determined with Typhoon FLA 9500 (GE 
Healthcare) and band quantifi cation was performed using Im-
ageQuant TL v7.01 software (GE Healthcare). Protein load was 
normalized using total protein fl uorescent signal. 
 Lipidomic analysis 
 Free cholesterol (FC) and TG content was analyzed by TLC, as 
previously described ( 26 ), in DM (N = 10) and nonDM (N = 8) 
subjects. Briefl y, the organic solvent was removed under a N 2 
stream and the lipid extract redissolved in dichloromethometane 
prior to TLC analysis that was performed on silica G-24 plates. 
The different concentrations of standards were applied to each 
plate. The chromatographic developing solution was heptane/
diethyl ether/acetic acid (74:21:4, v/v/v). Bands corresponding 
to FC and TG were quantifi ed using a computing densitometer 
(GS-800; Bio-Rad). 
 CE content and phospholipid species [lysophosphatidylcholine 
(LPC), lysophosphatidylethanolamine (LPE), lysophosphatidyl-
serine (LPS), phosphatidylcholine (PC), phosphatidylethanol-
amine (PE), phosphatidylserine (PS), and SM] were assessed by 
LC-MS analysis in DM (N = 10) and nonDM (N = 8) subjects. To 
this end, lipids from LDL fractions were extracted by a modifi ed 
Bligh and Dyer technique ( 27 ). After chloroform/methanol ex-
traction, lipid extracts were analyzed by LC-MS on an Agilent 
1200 HPLC system coupled to a 3200 Q-TRAP mass spectrome-
ter. For fatty acid analysis, hydrolysis and derivatization to tri-
methylaminoethyl (TMAE) esters were performed prior to the 
separation using a Varian Pursuit diphenyl column ( 28 ). Samples 
were ionized using an ESI source in the positive ionization mode, 
and quantifi cation was performed in the multiple reaction moni-
toring mode. CE and phospholipid analyses were performed on 
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smoking remained as independent factors for ApoA-I levels, 
with an R squared of 0.558. Unstandardized coeffi cients 
gave a   -value of   0.696 ( P < 0.0001) for the presence of 
diabetes and   0.134 ( P < 0.05) for tobacco smoking. 
 ApoA-I truncated form 
 MALDI-TOF analysis of the DM patients’ serum pro-
teome revealed a spot with a pI of 5.75 and an apparent 
molecular mass of approximately 26 kDa (spot 6 in  Fig. 2A ) 
that was identifi ed as ApoA-I with a score of 108 (10/23 
peaks matched, a sequence coverage of 34.8% and an in-
tensity coverage of 60.5%). This spot showed a 64% in-
crease in its intensity in DM patients ( P < 0.01;  Fig. 2B ), 
representing 4.8% of total ApoA-I in comparison with the 
1.3% in nonDM subjects. 
 Tryptic digestion of spots 1–5 of ApoA-I generated a 
peptide corresponding to aa residues 37-47 that was de-
tected as a peak of  m/z 1,235.63 ( Fig. 3 ). Spots 1–5 have 
been previously described in the literature ( 30 ) as the pro-
ApoA-I (spots 4 and 5 in  Fig. 1A, B ) and the mature ApoA-
I (spots 1–3 in  Fig. 1A, B ) forms of 28 kDa. The peak of  m/z 
1,235.63 was not detected in the mass spectra obtained 
from the digestion of spot 6 ( Fig. 2C ). As the molecular 
mass of spot 6 ( Fig. 2A ) suggested a truncated form of 
ApoA-I, we performed an in silico analysis using the Se-
quence Editor tool of BioTools (Bruker Daltonics; BioTo-
ols 3.02) simulating the tryptic sequential digestion of the 
N-terminal aas from ApoA-I. In this analysis, we obtained a 
theoretical set of peptides and their corresponding peak 
list (supplementary Table 1) that were compared with the 
experimentally obtained spectra. The theoretical pick list 
obtained from a truncation from aa 1 to aa 38 contained a 
peak of  m/z 1,422.735, corresponding to aas from 39 to 51 
( Fig. 3 ). This peak was found within the nonmatched peak 
list of spot 6. Moreover, the absence of the 38 fi rst aas cor-
responded with a molecular mass of 26.4 kDa, in agree-
ment with the molecular mass observed in 2-DE gels of 
spot 6 [ApoA-I  (1-38)]. 
 Multiple linear regression analysis, including those vari-
ables statistically signifi cant for ApoA-I  (1-38) intensity in 
the bivariate analysis (hypertension, dyslipemia, and insu-
lin and Ezetrol treatment) showed that only the presence 
of diabetes remained as an independent factor for ApoA-
I  (1-38) levels, with an R squared of 0.362 and an unstan-
dardized coeffi cient with a   -value of 0.632 ( P < 0.01). 
 Differential ApoA-I  (1-38)-associated lipoprotein profi le 
in DM patients 
 When total serum, LPDS, HDL, and LDL samples were 
analyzed in a 2-DE zoom of pH between 4.7 and 5.9, this 
ApoA-I  (1-38) form was detected in both serum and LDL, 
but not in LPDS or in HDL ( Fig. 4A ). The presence of the 
ApoA-I  (1-38) form in LDL extracts was confi rmed by 
Western blot analysis of both 1-DE and 2-DE ( Fig. 4B ). The 
absence of ApoA-I  (1-38) in VLDL particles was con-
fi rmed by MALDI-TOF and Western blot analysis (supple-
mentary Fig. 2). 
 The analysis of the LDL sub-proteome (2-DE analysis in 
the range of 150–20 kDa; supplementary Fig. 3) revealed a 
 All animals were purchased from Charles River Laboratories. 
All procedures fulfi lled the criteria established by the  Guide for the 
Care and Use of Laboratory Animals published by the US National 
Institutes of Health (NIH Publication No.85-23, revised 1996) 
and were approved by the Internal Animal Committee Review 
Board. 
 Frozen liver samples from diabetic and control animals were 
pulverized and homogenously distributed in aliquots for protein 
extraction. Pulverized tissue was homogenized in a lysis buffer 
containing 0.4% chaps for the cathepsin D activity assay, and in a 
urea/thiourea/chaps buffer for the 2-DE analysis. Protein con-
centration was measured using the 2D-Quant kit (GE Health-
care). Cathepsin D activity in hepatic protein extracts was 
measured using a commercially available cathepsin D assay kit 
(Sigma) following the provider’s instructions. 
 Statistical analysis 
 Data are expressed as median [interquartile range] unless 
stated otherwise. N indicates the number of subjects/animals 
tested. Statistical analysis was performed with Stat View 5.0.1 soft-
ware. Statistical differences between groups were analyzed by the 
nonparametric Mann-Whitney or Kruskal-Wallis tests for multi-
ple comparisons. Chi-square test (  2 ) or Fisher’s exact test, when 
any of the expected values were <5, were used for categorical vari-
ables.  P   0.05 was considered signifi cant. 
 To determine correlation between ApoA-I, anthropometric 
parameters (age and gender), risk factors (hypertension, dyslipe-
mia, tabaco), and background medication, we performed a bi-
variate analysis (correlation or  t -test) followed by a multiple 
linear regression model (stepwise selection of variables), includ-
ing those variables statistically signifi cant in the bivariate analysis 
to assess the most parsimonious model. 
 RESULTS 
 Characteristics of the studied population 
 Characteristics of DM and control nonDM patients par-
ticipating in this study are shown in  Table 1 . Patients were 
treated as per guideline recommendations. 
 ApoA-I proteomic profi le in DM patients 
 Proteomic analysis by 2-DE (pH ranges 4–7 and 4.7–5.9; 
supplementary Fig. 1) of serum samples revealed ApoA-I 
as a cluster of fi ve spots with the same apparent molecular 
mass of 28 kDa and a isoelectric point (pI) range between 
5 and 5.75, as previously reported ( 23 ). By MALDI-TOF 
analysis, the fi ve spots were identifi ed as ApoA-I in both 
DM and nonDM subjects. The ApoA-I proteomic profi le in 
both groups was compared ( Fig. 1A, B ). Spot 5 showed a 
46% increase in its intensity in DM patients when com-
pared with nonDM subjects ( P < 0.01;  Fig. 1C ). This signifi -
cant difference was not picked-up by ELISA determination 
of ApoA-I serum levels that gave signifi cantly lower values 
in DM patients when compared with nonDM individuals 
(DM: 69.8 [59.8–83.5] mg/dl vs. nonDM: 139.7 [119.0–
155.3] mg/dl,  P < 0.0001;  Table 1 ). 
 Multiple linear regression analysis, including those vari-
ables statistically signifi cant for ApoA-I serum levels in the 
bivariate analysis (risk factors and background medication), 
showed that only the presence of diabetes and tobacco 
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in all the LDL fractions reproduced the results obtained 
with total LDLs, with a signifi cant increase in DM patients 
( P < 0.05;  Fig. 5C ). There was a differential distribution pro-
fi le of lipid species in LDL subclasses between DM and 
nonDM subjects ( Table 2 ). DM patients showed a higher 
content of PSs and LPSs in the LDL2 subfraction when 
compared with nonDM subjects ( P < 0.05). The LDL3 sub-
fraction depicted a signifi cant increase in PCs, LPCs, and 
SMs, together with a decrease in PEs and LPEs in DM pa-
tients when compared with the nonDM group ( P < 0.05). 
 Cathepsin D cleaves ApoA-I and shows increased liver 
activity in diabetic rats 
 Data mining analysis opened tentative pathways to ex-
plain the posttranscriptional truncation of ApoA-I. An ex-
perimental model of diabetes was used to proof the concept. 
First, the proteomic profi le of rat serum revealed the pres-
ence of two ApoA-I forms of 28 and 26 kDa, similar to the 
forms (molecular mass) observed in human serum (supple-
mentary Fig. 6A). Rat ApoA-I behaves differently in the pro-
teomic profi le due to the already described differences in 
the pI of the pro-ApoA-I (full-length) and the mature ApoA-
I forms. As stated in the protein database UniProt, the ma-
ture form of human ApoA-I (aas 25-267; SwissProt accession 
number, P02647) has a more acid pI (5.27) than pro-ApoA-
I (full-length; aas 19-267; pI 5.45). In contrast, in rat, the 
mature form of ApoA-I (aas 25-259; accession number, 
P04639) has a more basic pI (5.51) than pro-ApoA-I (full-
length; aas 19-259; pI 5.41), giving an inverted proteomic 
profi le in the 2-DE analysis as a result. Therefore, our results 
showed that the truncated low molecular mass ApoA-I form 
of 26 kDa is detected in both cases underneath the full-length 
 TABLE 1. Background description of DM patients and nonDM individuals 
DM (N = 55) NonDM (N = 59)  P 
Age 55 ± 1.4 62 ± 1.1 <0.0001
Sex (females/males) 23/32 14/44 <0.05
Risk factors (%)
 Diabetes (type 1/type 2) 100 (35/65) 0 <0.0001
 Dyslipemia 87 52 <0.0001
 Hypertension 93 21 <0.0001
 Tobacco smoking 49 17 <0.0001
History of CVD (%) 4 0 NS
BMI 26 ± 0.4 27 ± 0.5 <0.05
Total-C (mg/dl) 182 ± 4.5 217 ± 5.3 <0.0001
HDL-C (mg/dl) 53 ± 2.2 49 ± 1.9 NS
LDL-C (mg/dl) 101 ± 3.4 143 ± 4.6 <0.0001
TGs (mg/dl) 129 ± 17.1 130 ± 12.0 NS
ApoA-I (mg/dl) 69 ± 2.9 147 ± 5.9 <0.0001
Glucose (mg/dl) 157 ± 7 87 ± 2.8 <0.0001
HbA1c (%) 7.6 ± 0.1 — —
Background medication (%)
 OADs 58 0 <0.0001
 INS 80 0 <0.0001
 Statins 82 26 <0.0001
 Antiaggregants 36 0 <0.0001
 ACEIs 56 7 <0.0001
 A2RAs 62 3 <0.0001
 Ca 2+ antagonists 42 0 <0.0001
   -blockers 7 2 NS
 Ezetrol 29 0 <0.0001
Data are expressed as mean ± SEM. ACEIs, angiotensin-converting enzyme inhibitors; A2RAs, angiotensin 2 
receptor antagonists; INS, insulin; OADs, oral antidiabetic drugs; Total-C, total-cholesterol; HDL-C, HDL-cholesterol; 
LDL-C, LDL-cholesterol.
signifi cant increase in the intensity of ApoA-I  (1-38) spot 
in DM patients when compared with nonDM individuals 
(DM: 1.74 [1.54–2.04] AU vs. nonDM: 1.01 [0.87–1.14] 
AU;  P < 0.05;  Fig. 4C ). ApoB-100 (molecular mass of 
515 kDa) does not appear because it is out of the range of 
the 2-DE analysis used here, that was selected to obtain the 
ApoA-I profi le. 
 Lipidomic characterization 
 A lipidomic approach was further used to characterize 
LDL preparations from DM and nonDM subjects. LDLs 
from DM patients showed no signifi cant changes in the con-
tent of TG and FC levels measured by TLC (supplementary 
Fig. 4A), but showed higher CE levels measured by LC-MS 
than nonDM individuals ( P < 0.05; supplementary Fig. 4B). 
 Lipoprotein subclasses and ApoA-I  (1-38) 
 In order to analyze whether ApoA-I  (1-38) was differen-
tially distributed in the different LDL subclasses and to 
probe its absence in all HDL subclasses, proteomic analysis 
of four LDL (LDL1–LDL4) and two HDL (HDL2 and 
HDL3) subtypes was performed. ApoA-I  (1-38) was not de-
tected in the HDL2 or in the HDL3 subfraction (supple-
mentary Fig. 5). When the four LDL subclasses were 
analyzed (pI range of 4–7 and 10% PAGE), ApoA-I  (1-38) 
was differentially distributed between DM and nonDM sub-
jects ( Fig. 5A ). In nonDM individuals, ApoA-I  (1-38) was 
equally distributed along the different LDL subclasses, 
while DM patients depicted a signifi cant increase in the in-
tensity of ApoA-I  (1-38) in the denser LDL subtypes (LDL3 
and LDL4;  P < 0.05;  Fig. 5B ) when compared with the 
nonDM group. The sum of the intensities of ApoA-I  (1-38) 
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vitro experiments with full-length recombinant ApoA-I 
and cathepsin D-cleaved ApoA-I. Truncated ApoA-I showed 
a 39% lower binding ability toward HDLs than the full-
length ApoA-I. On the contrary, cathepsin D-cleaved 
ApoA-I exhibited a 47% higher binding capacity toward 
LDLs when compared with full-length ApoA-I ( P < 0.0001 
for all comparisons;  Fig. 6A ). 
 We further analyzed the potential functional implica-
tion of this increased binding affi nity of truncated ApoA-I 
toward LDLs by measuring the antioxidant capacity against 
LDL oxidation of both full-length and cathepsin D-cleaved 
ApoA-I. Cathepsin D-cleaved ApoA-I truncation resulted 
in a 1.4-fold decrease in its antioxidant capacity, when 
compared with full-length ApoA-I ( P < 0.0001;  Fig. 6B ). 
 DISCUSSION 
 The functional activity of HDLs has been repeatedly re-
ported as defective and as a contributor to the high cardio-
vascular risk of DM patients ( 21 ). In this study, we have 
approached the investigation by proteomics and lipido-
mics of the ApoA-I profi le and found important changes 
in its isoform distribution pattern in DM patients. Interest-
ingly, here we describe for the fi rst time the presence of 
ApoA-I  (1-38) in serum, a form that is signifi cantly in-
creased in DM patients. ApoA-I is modifi ed at a post-
translational level ( 32 ) and several environmentally/
metabolically related modifi cations have been reported, 
such as fatty acid acylation ( 33 ) and oxidation ( 34 ). In DM 
patients, attention has been focused on nonenzymatic 
protein glycation and advanced glycation end product 
(AGE) formation. Both are related to hyperglycemia in 
type 1 and type 2 diabetes, where AGE adducts are associ-
ated with ApoA-I, impairing its ability to activate LCAT, 
ApoA-I form (pro-ApoA-I). As in humans, diabetic rats 
showed signifi cantly higher levels of the ApoA-I form of 
26 kDa in serum than nondiabetic rats ( P < 0.05; supple-
mentary Fig. 6B). This observation led us to investigate the 
potential enzymes involved in the cleavage of both human 
and rat ApoA-I molecules. In silico analysis using MEROPS 
database ( 31 ) revealed cathepsin D as the only enzyme 
able to cleave ApoA-I sequence from both species (supple-
mentary Fig. 6C). 
 In vitro treatment of ApoA-I with cathepsin D abolished 
the 28 kDa ApoA-I form and led to the detection of a lower 
molecular mass band in agreement with the 2-DE profi le 
of both ApoA-I forms (supplementary Fig. 7A). The activ-
ity of cathepsin D was controlled by using hemoglobin di-
gestion as a positive control. 
 As ApoA-I is synthesized in the liver, hepatic cathepsin 
D activity in diabetic rats was analyzed in order to test 
whether ApoA-I could be cleaved after synthesis. Diabetic 
rats showed a signifi cant increase in hepatic cathepsin D 
activity when compared with control animals (diabetic 
rats: 6.1 [4.2–6.7] vs. control animals: 3.71 [2.7–4.8];  P < 
0.05; supplementary Fig. 7B ). 
 Additionally, the ApoA-I proteomic profi le (2-DE fol-
lowed by ApoA-I Western blot analysis) of rat liver samples 
revealed the presence of the same ApoA-I forms of 28 and 
26 kDa (supplementary Fig. 7C) with the same distribu-
tion as the one detected in rat serum. Diabetic rats showed 
a 2-fold increase in the hepatic content of the ApoA-I form 
of 26 kDa compared with control animals ( P < 0.05; sup-
plementary Fig. 7D). 
 Cathepsin D-cleaved ApoA-I exhibits increased LDL 
binding ability and diminished antioxidant properties 
 In order to proof the differential affi nity toward differ-
ent lipoproteins of truncated ApoA-I, we performed in 
 Fig.  1. Representative serum 2-DE images (pI range 4–7, 10% PAGE) of ApoA-I spots in nonDM subjects 
(N = 6) (A) and DM-patients [N = 12 (6 type 1 and 6 type 2)] (B). C: Box-plot diagrams showing the intensity 
of each spot in both groups. Spot 5 was signifi cantly increased in DM patients. ** P < 0.01. 
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ApoA-I to the particle size of HDLs ( 10 ). Therefore, the 
lack of the 38 fi rst aas detected in ApoA-I  (1-38) may af-
fect the transition from lipid-free ApoA-I to spherical HDL 
particles ( 40 ) ( Fig. 7 ), potentially impairing the reverse 
cholesterol transport ability and facilitating its binding to 
LDL particles. Indeed, our in vitro experiments have dem-
onstrated a diminished binding ability of the truncated 
ApoA-I form to HDLs, together with an important increase 
in its binding to LDLs, when compared with full-length 
ApoA-I. These results indicate that, after truncation, there 
is a selective binding of ApoA-I  (1-38) to LDLs and not an 
incorporation into LDLs during the particle formation 
process, as ApoA-I  (1-38) is not associated to VLDLs. 
 The N-terminal aas are necessary for formation of large 
HDL complexes, and their absence leads to less stable 
HDL particles ( 41 ). Although, traditionally, ApoA-I has 
been related to HDLs as the main protein component in 
these micelles, previous studies have reported the pres-
ence of this apolipoprotein in LDL particles ( 25 ). Interest-
ingly, in the present study, DM patients showed a strong 
decrease in total ApoA-I serum levels, measured by 
ELISA, when compared with healthy individuals inde-
pendently of background medication. Moreover, DM pa-
tients showed similar HDL-cholesterol levels to the control 
the enzyme responsible for converting nascent HDLs into 
mature HDLs ( 35 ). AGEs seem to accelerate the develop-
ment of CAD ( 36 ). ApoA-I modifi cation studies have also 
shown that the most basic forms are the less mature iso-
forms of the protein ( 30 ). Interestingly, we have detected 
an increase in the basic less mature form of ApoA-I in 
diabetics. 
 Proteolysis is thought to play an important role in most 
types of amyloidoses, in atherosclerosis, and in neurode-
generative diseases. In fact, macrophage metalloprotein-
ases degrade HDL-associated ApoA-I at both the N and 
C termini in coronary patients ( 37 ). Intriguingly, ApoA-
I  (1-38), lacking residues 1-38, is signifi cantly increased in 
serum samples of DM patients, and it is found associated 
to LDL lipoproteins and not to VLDL or HDL micelles. 
In vitro studies have demonstrated that the experimental 
deletion of residues 1-43 from ApoA-I results in a less 
stable tertiary structure than full-length ApoA-I ( 38 ). 
Moreover, the deletion mutants lacking residues 1-41 
and 1-59 showed altered lipid binding ability compared 
with wild-type ApoA-I ( 39 ). The N-terminal 44 aa sequence 
of ApoA-I is predicted to be responsible for the stabiliza-
tion of soluble ApoA-I; and recently, it has been demon-
strated that residues 35-49 play a role in the adaptation of 
 Fig.  2.  A: Representative serum 2-DE image (pI range 4–7, 10% PAGE) showing ApoA-I spot 6 at 26 kDa. B: Box-plot diagram showing 
the increase in spot 6 intensity in DM patients. ** P < 0.01. C: MALDI-TOF spectra of human serum ApoA-I. D: Enlarged image showing the 
absence of the m/z 1,235.63 peak in spot 6 compared with spots 1–5. 
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increase ApoA-I  (1-38) that is associated to LDL particles 
in DM patients later on, due to its increased binding abil-
ity . Previous studies have demonstrated an increase in ca-
thepsin D activity to cleave hemoglobin in serum samples 
of DM patients ( 43 ). Herein, we have found increased ca-
thepsin D activity in the liver of diabetic rats together with 
an increased content of truncated ApoA-I, both in liver 
and serum. These fi ndings, together with the previously 
described increased susceptibility of the N-terminal region 
of lipid-free ApoA-I to protease cleavage ( 44 ), leads us to 
speculate that once synthesized, ApoA-I is cleaved by ca-
thepsin D either at the liver or in the circulation, pro-
ducing an ApoA-I particle lacking the fi rst 38 aas, with 
increased affi nity for LDLs. Thus, this truncation may lead 
to the binding of the ApoA-I  (1-38) form to LDL parti-
cles, yielding an LDL population more prone to oxidation 
group, highlighting the discordance between levels, struc-
ture and function, and the relevance of HDL quality rather 
than its quantity ( 4 ). These results emphasize the poten-
tial implication of this decrease in ApoA-I levels in the 
increased cardiovascular risk of DM patients and the in-
consistency of measuring cholesterol transported by HDLs 
as an index of HDL particle content, and even more of 
its afforded atheroprotection. Indeed, some studies are al-
ready relating not HDL but Apo A-I levels to a worse prog-
nosis in DM patients ( 42 ). Furthermore, this and previous 
( 23 ) studies of our group underscore that the measure-
ment of specifi c forms (immature and truncated forms 
in diabetes) would better help in the prognostic value of 
ApoA-I. 
 In this study, we have also demonstrated for the fi rst 
time that cathepsin D can cleave ApoA-I and potentially 
 Fig.  3. Scheme showing the truncation of aas 1-38 in ApoA-I sequence and the fragments corresponding 
to the peaks detected in MALDI-TOF analysis. *Previously described ApoA-I forms ( 30 ) include: Pro-ApoA-I 
(aas 19-267) that corresponds to spots 4 and 5 in  Fig. 1A, B , and mature ApoA-I (aas 25-267) that corre-
sponds to spots 1, 2, and 3 in  Fig. 1A, B . Spot 6 in  Fig. 2A (identifi ed here), corresponds to aas from 39 to 
267, ApoA-I  (1-38). 
 Fig.  4. A: Representative 2-DE image (pI range 
4.7–5.9, 15% PAGE) of ApoA-I profi le in serum, 
LPDS (N = 3 per group), HDL (DM, N = 6; nonDM, 
N = 9), and LDL (N = 5 per group) samples showing 
ApoA-I  (1-38) presence in serum and LDLs. B: Rep-
resentative 1-DE and 2-DE Western blot (WB) images 
showing ApoA-I at 28 and 26 kDa in LDL samples. C: 
Box-plot diagram of the ApoA-I  (1-38) increase in 
LDLs of DM patients. * P < 0.05. 
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CE transfer from HDLs to small dense LDLs ( 50 ). Indeed, 
our lipidomic analysis has revealed an increase in the CE 
content in LDLs from DM patients. Furthermore, it has 
been shown that small dense LDL particles exhibit a 
higher affi nity for arterial proteoglycans, a fact that could 
increase its susceptibility to being retained in the intima, a 
determinant step in atherogenesis ( 51 ). Importantly, our 
proteomic profi ling approach has revealed that DM pa-
tients have higher ApoA-I  (1-38) content in the denser 
LDL fractions (LDL3 and LDL4) probably contributing to 
the modifi cation of such lipoproteins in relation to diabe-
tes. The increase in the content of ApoA-I  (1-38) together 
with the decrease in total ApoA-I serum levels could in-
duce an increase in the susceptibility to LDL atherogenic 
modifi cations, as ApoA-I has been postulated to enter the 
vessel wall and protect LDLs in the arterial wall ( 52 ). In 
this context, the increase in truncated ApoA-I in DM pa-
tients could lead to a higher LDL oxidation level, as sug-
gested by our in vitro studies. In fact, previous studies have 
proposed the existence of several ApoA-I truncated forms 
and their potential implication in the assessment of car-
diovascular risk ( 44 ). In addition, our lipidomic analysis 
 Fig.  5.  A: Representative 2-DE image (pI range 4–7, 10% PAGE) of ApoA-I in LDL subclasses in DM pa-
tients and nonDM subjects (30 DM patients and 30 nonDM individuals pooled in three groups of 10 subjects 
each). Bar diagrams showing the signifi cant increase in ApoA-I  (1-38) intensity in LDL3 and LDL4 of DM 
patients (B) and in the sum of ApoA-I  (1-38) intensity in all the LDL subfractions (C). * P < 0.05. 
and contributing to the already described modifi ed LDL 
particles in DM patients. Indeed, it has been suggested 
previously that cathepsin D could induce hydrolytic modi-
fi cations of LDLs, favoring the formation of foam cells in 
the intima of human arteries ( 45 ). Moreover, cathepsin D 
has been shown to be released by atherosclerotic plaques, 
and increased plasma levels have been found in acute 
coronary syndrome patients ( 46 ). Although we have found 
a potential role of cathepsin D in the formation of ApoA-
I  (1-38), we cannot exclude the implication of other 
enzymes. 
 Several studies have reported different LDL modifi ca-
tions in diabetics due to oxidation and glycosylation, re-
sulting in the presence of more atherogenic LDL particles 
in these patients ( 47 ). Indeed, the increased cardiovascu-
lar risk of DM patients has been related to the presence 
of small dense LDL particles ( 48 ), which have been shown 
to be more atherogenic and may explain, at least in part, 
the higher risk of those patients even having similar LDL-
cholesterol plasma concentrations than control subjects 
( 49 ). Specifi cally, the formation of small dense LDL parti-
cles in type 2 diabetes has been attributed to a preferential 
 TABLE 2. Lipidic distribution profi le in LDL subclasses of DM patients and nonDM individuals 
Lipid Content (  g/mg of protein)
LDL1 LDL2 LDL3 LDL4
NonDM
 CE 1,884.1 [1,477.8–2,290.5] 1,251.0 [8,91.0–1,704.2] 906.9 [812.1–988.0] 2,536.5 [2,445.7–2,627.3]
 PC, LPC, SM 200.7 [195.3–206.1] 121.3 [107.3–137.8] 176.8 [173.6–180.2] 278.8 [256.7–300.9]
 PE, LPE 3.3 [3.0–3.6] 1.2 [1.0–1.7] 0.8 [0.7–1.0] 1.2 [1.1–1.3]
 PS, LPS 31.9 [29.1–34.7] 8.0 [6.9–11.6] 3.5 [3.3–6.8] 26.6 [18.1–35.1]
DM
 CE 774.9 [748.5–801.4] 1,610.5 [1,384.4–1,641.9] 1,319.3 [1,011.4–1,408.2] 1,882.0 [1,383.5–2,250.4]
 PC, LPC, SM 296.2 [295.6–296.9] 256.1 [202.8–350.3] 233.7 [221.1–235.5] a 324.3 [226.2–345.7]
 PE, LPE 1.7 [1.6–1.7] 0.8 [0.7–0.8] 0.5 [0.5–0.5] a 1.1 [1.0–1.2]
 PS, LPS 42.4 [37.4–47.4] 19.1 [18.8–20.5] a 8.1 [7.9–9.6] 19.3 [17.7–19.5]
Data are expressed as median [interquartile range].
 a P = 0.049, Mann-Whitney, DM versus NonDM.
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 Fig.  6. Bar diagrams showing: the differential binding ability of full-length and cathepsin D-cleaved ApoA-I 
to HDLs and LDLs (*** p <0.0001 for all comparisons; N = 3 independent experiments) (A); and the signifi -
cant decrease in ApoA-I antioxidant capacity against LDL oxidation after cathepsin D truncation (*** P < 
0.0001 vs. LDL; § P < 0.0001 vs. full-length ApoA-I; † P < 0.0001 vs. truncated ApoA-I; N = 3 independent ex-
periments) (B). 
has revealed changes in the content of several lipid species 
in different LDL subclasses, with a specifi c increase of the 
proinfl ammatory molecule LPC, among others, in LDL3 of 
DM patients. Interestingly, LPC has previously been shown 
to be associated with oxidized LDL particles playing a key 
role in atherosclerosis and the infl ammatory response ( 53 ). 
 The main limitation of the present study refers to the 
existence of differences in the baseline characteristics be-
tween DM and nonDM patients. However, despite the po-
tential infl uence of these parameters in ApoA-I metabolism, 
the multivariate statistical analysis has revealed the pres-
ence of diabetes as the main parameter infl uencing ApoA-
I  (1-38) levels. 
 Previous studies have already proved the increased ath-
erogenic properties of small dense LDL particles of DM 
patients ( 54 ). This study highlights the potential relevance 
of ApoA-I truncated forms in relation to this increased 
cardiovascular risk of DM patients. Moreover, our results 
point to the potential implication of cathepsin D in ApoA-
I  (1-38) formation. Possibly, other proteases may also 
cleave ApoA-I sequence at the same site. 
 Unfortunately, the amount of material obtained in the 
2-DE analysis corresponding to ApoA-I  (1-38) is too low 
to allow us to perform N-terminal sequencing analysis. 
Nevertheless, the molecular mass profi le observed in the 
2-DE analysis agrees with a truncated ApoA-I form that has 
also been confi rmed by the differential trypsin digestion 
peptide profi le observed in MS analysis. 
 In summary, despite the limitations of 2-DE approaches 
for the study of such a complex sample like serum, by care-
ful use of biochemical analysis, we have obtained useful 
complementary information about the presence of pro-
tein variants in diabetes. Thus, we have described, for the 
fi rst time, the increase of a 26 kDa N-terminal truncated 
form of ApoA-I that we have named ApoA-I  (1-38) that 
associates to the denser LDL particles in DM patients 
which may have effects in lipoprotein particle turnover, 
increase LDL susceptibility to oxidation, and further con-
tribute to a higher cardiovascular risk. The presence of 
cleaved ApoA-I variants is closely related to the incidence 
of chronic diseases such as diabetes, atherosclerosis, and 
ageing ( 55 ). Therefore the potential role of this truncated 
 Fig.  7. Scheme of the canonical pathway of the con-
version of an ApoA-I molecule into mature HDL mi-
celles showing the proposed pathway of the binding 
of ApoA-I  (1-38) to LDL particles. 
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ApoA-I form in the pathogenesis of CVD deserves further 
investigation.  
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